A comparative study of the transfusion effect of single donor apheresis platelets versus random donor platelets in the management of severe dengue infection in children

Chandra Deve Varma B. S. K. Buddharaju, Gujjarlamudi Chandrakanth, Konala Venkata Shiva Reddy, Vundela Lokeswara Reddy, Lambadi Shanmukha Som


Background:  The national vector-borne diseases control programme (NVBDCP) dengue clinical care guidelines 2014 clearly specify the indications for platelet transfusion in dengue fever. The goal of the study was to see how successful guideline-driven platelet transfusion was, as well as whether single donor platelet (SDP) transfusion was superior to random donor platelet transfusion (RDP), which was widely thought but unproven.

Methods: Two ml of the patient's blood were collected in EDTA tubes at two distinct times: once before the transfusion and the other 24 hours afterwards and the data were assessed using corrected count increments (CCI), percentage recovery (PR) and other criteria.

Results: Platelet increments were substantially larger with SDP transfusions at 24 hours than with RDP transfusions (p<0.01 for 24 hours post-transfusion period). However, in both groups, the corrected count increment and percentage recovery were nearly identical and the difference was statistically insignificant.

Conclusions: Although post-transfusion increments were considerably higher in SDP patients than in RDP patients, the CCI and PR were similar in both groups of patients. When it comes to the number of donors exposed to patient and leukoreduction, SDP is superior to RDP in terms of logistics. However, in developing countries, SDP may be advised only in selected patients based on accessibility and affordability, due to their high cost and higher technical competence required.


Apheresis, Compatible, Homeostasis, Leukoreduction, Platelet concentrate

Full Text:



Sherill J. Slichter MD. Platelet transfusion therapy. Hematology/ Oncology Clinics of North America. 1990;4:291-311.

World Health Organization. Guidelines for Treatment of Dengue Fever/Dengue Hemorrhagic Fever. Recognition of Dengue Fever/Dengue Hemorrhagic Fever (DF/ DHF). Grading the Severity of Dengue Infection. New Delhi: World Health Organization; 2009. DHF_guidelines. Available at: 10665/44188 Accessed on 28 March 2022.

World Health Organization. Dengue and Dengue Hemorrhagic Fever. WHO Fact Sheet. Geneva: WHO; 2008. Available at: news-room/fact-sheets/detail/dengue-and-severe-dengue. Accessed on 28 March 2022.

Handbook for clinical management of dengue. 1. Dengue – therapy. 2. Dengue – diagnosis. 3. Clinical medicine. 4. Handbooks. I. World Health Organization. ISBN 978 92 4 150471 3 (NLM classification: WC 528) © World Health Organization 2012. Available at: https://apps.;sequence=1. Accessed on 28 March 2022.

Wallace EL, Churchill WH, Surgenor DM. Collection and transfusion of blood and blood components in the United States. 1992.

Rinder HM, Smith BR. In vitro evaluation of stored platelets: Is there hope for predicting post transfusion platelet survival and function? Transfusion. 2003;43(1):2-6.

Hogman CF, Eriksson L, Wallvik J, Payrat JM. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5 CPD Erythrosol Opti-system. Vox Sang. 1997;73:212-9.

Unagar CA, Patel SG, Patel KA, Pandya AN, Jarag MA, Patel JN et al. Transfusion effect of random donor platelet and single donor platelet in thrombocytopenic patients at tertiary care hospital of South Gujarat. Int J Res Med Sci. 2017;5(7):3033-7.

O'Connell B, Lee EJ, Schiffer CA. The value of 10 minutes post-transfusion platelet counts. Transfuse. 1998;28:66-7.

Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG et al. A prospective randomized study of three types of platelet concentrates in patients with hematological malignancy, corrected platelet count increments, and frequency of non-hemolytic febrile transfusion reactions. Transfusion Med. 1997;7(1):33-9.

Singh RP, Maratha N, Amphora P, Dash S. Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patients. Indian J Hematol Blood Transfusion. 2008;24(1):16-22.

Kumar ND, Tomar V, Singh B, Kela K. Platelet transfusion practice during dengue fever epidemic. Indian J Pathol Microbiol. 200;43:55-60.

Norol F, Bierling P, Roudot-Thoraval F, Lecoeur F, Rieux C, Lavaux A et al. Platelet transfusion: a dose-response study. Blood. 1998;92(4):1448-53.

Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2007;40(5):461-4.

Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600-13.

Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18(3):153-67.

Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M et al. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion. 2006;46(6):903-11.

Kansay S, Singh H. Effect of the introduction of single-donor apheresis platelets in dengue management: A comparative analysis of two consecutive dengue epidemics. Journal of Laboratory Physicians. 2018;10(2):173-8.

Ahsan T, Jabeen R, Rehman UL, Banu Z, Jaffri SA. Platelet Transfusion; What and When to Transfuse, a Dilemma of Clinical Practice. Intern Med. 2015;5:181.